Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGRAL: THR-687 vs Aflibercept for DME
NCT05063734Phase 2Terminated
- Sponsor
- Oxurion
- Start
- Aug 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of THR-687 in diabetic macular edema (DME), sponsored by Oxurion. Started Aug 2021; status: terminated.
02
Drugs
THR-687
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05063734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063734.